Partial
Needs Review
Patient Risk:
Moderate
Summary
Several statements about PR interval prolongation, cardiac conduction warnings, and cautions with concomitant conduction-affecting medications align with the label excerpts. However, many interaction/monitoring statements use absolute or “typically” phrasing not explicitly supported by the provided label text, some claims about other AEDs/patent sites are not supported, and multiple clinically important specifics (e.g., starting lacosamide in AV block/sick sinus/marked bradycardia) are inconsistent with the limited contraindication information and/or not supported by the provided excerpts.
Category Scores
Accurate Statements
Lacosamide can slow conduction through the heart.
Label excerpt 5.3 states PR prolongation, AV block, and reports of cardiac arrhythmias including bradycardia and AV block.
Lacosamide can prolong the PR interval on an electrocardiogram.
Label excerpt 5.3: dose-dependent prolongations in PR interval observed; label excerpt 12.2: small, dose-related increase in mean PR interval.
The effect of lacosamide on PR interval is usually modest at normal doses.
Label excerpt 12.2: small, dose-related increase in mean PR interval (supports modest effect characterization).
The effect of lacosamide on PR interval can become clinically relevant in people with existing conduction abnormalities.
Label excerpt 5.3: VIMPAT should be used with caution in patients with underlying proarrhythmic conditions; discusses PR prolongation, AV block risk.
The effect of lacosamide on PR interval can become clinically relevant in people taking other drugs that slow conduction.
Label excerpt 7.2: VIMPAT should be used with caution in patients on concomitant medications that affect cardiac conduction because of risk of AV block, bradycardia, or ventricular tachyarrhythmia.
Combination of lacosamide with the above agents may increase the chance of bradycardia.
Label excerpt 7.2: risk of AV block, bradycardia, or ventricular tachyarrhythmia with concomitant medications that affect cardiac conduction.
Combination of lacosamide with the above agents may increase the chance of heart block.
Label excerpt 7.2: risk of AV block with concomitant medications that affect cardiac conduction.
Patients on beta-blockers, calcium-channel blockers (verapamil/diltiazem), or certain antiarrhythmics (amiodarone/flecainide) may require closer ECG monitoring when lacosamide is started or the dose is increased.
Label excerpt 7.2 supports caution with concomitant medications affecting cardiac conduction; however explicit “closer ECG monitoring” and the listed drugs are not explicitly stated in the provided excerpts.
Doctors typically obtain a baseline ECG when lacosamide is introduced or titrated with other drugs.
Label excerpt 5.3/7.2 discuss caution and risk but the provided excerpts do not explicitly mandate baseline ECG.
Unsupported Statements
The effect of lacosamide on PR interval is usually modest at normal doses.
Supported only as “small, dose-related increase in mean PR interval” (12.2), but “usually modest at normal doses” is not explicitly stated as such in the provided label excerpts.
The effect of lacosamide on PR interval can become clinically relevant in people with existing conduction abnormalities.
Label supports caution and PR prolongation/AV block risks, but does not explicitly say “clinically relevant” or identify specific groups in these exact terms in the provided excerpts.
Beta-blockers can add to PR-interval prolongation when combined with lacosamide.
Label excerpt 7.2 supports caution with medications that affect cardiac conduction, but the provided excerpts do not explicitly list beta-blockers or state they “add to PR-interval prolongation.”
Calcium-channel blockers can add to PR-interval prolongation when combined with lacosamide.
Label excerpt 7.2 is general about concomitant medications affecting cardiac conduction; the provided excerpts do not explicitly state calcium-channel blockers “add to PR-interval prolongation” or list classes/detailed outcomes for PR specifically.
Verapamil can add to PR-interval prolongation when combined with lacosamide.
No verapamil-specific claim appears in the provided label excerpts.
Diltiazem can add to PR-interval prolongation when combined with lacosamide.
No diltiazem-specific claim appears in the provided label excerpts.
Amiodarone can add to PR-interval prolongation when combined with lacosamide.
No amiodarone-specific claim appears in the provided label excerpts.
Flecainide can add to PR-interval prolongation when combined with lacosamide.
No flecainide-specific claim appears in the provided label excerpts.
Combination of lacosamide with the above agents may increase the chance of fainting.
Label excerpts include a syncope section (5.4) but do not explicitly connect fainting risk to concomitant conduction-affecting drugs as stated.
Patients on beta-blockers, calcium-channel blockers (verapamil/diltiazem), or certain antiarrhythmics (amiodarone/flecainide) may require closer ECG monitoring when lacosamide is started or the dose is increased.
Provided label excerpts support caution with medications that affect cardiac conduction (7.2) but do not explicitly mention “closer ECG monitoring,” “when started,” or “dose increased,” nor list these specific drug classes/agents.
Many people taking ACE inhibitors experience no clinically important interaction with lacosamide.
No ACE-inhibitor interaction statements appear in the provided label excerpts.
Many people taking ARBs experience no clinically important interaction with lacosamide.
No ARB interaction statements appear in the provided label excerpts.
Many people taking statins experience no clinically important interaction with lacosamide.
No statin interaction statements appear in the provided label excerpts.
Many people taking low-dose aspirin experience no clinically important interaction with lacosamide.
No aspirin interaction statements appear in the provided label excerpts.
The key variable for interaction risk with lacosamide is whether the heart medication slows conduction.
Label 7.2 supports caution with medications that affect cardiac conduction, but does not present a single “key variable” framework or limit interaction risk to conduction alone in the provided excerpts.
The key variable for interaction risk with lacosamide is whether the heart medication markedly depresses cardiac function.
Not supported by the provided label excerpts.
If the heart medication does not slow conduction or markedly depress cardiac function, the added risk from lacosamide is usually small.
Not stated in the provided label excerpts.
Doctors typically repeat an ECG after lacosamide is introduced or titrated.
No explicit ECG repetition instruction appears in the provided label excerpts.
Blood pressure checks at follow-up visits can help detect emerging conduction issues early.
Not supported by the provided label excerpts.
Heart-rate checks at follow-up visits can help detect emerging conduction issues early.
Not supported by the provided label excerpts.
New dizziness should prompt immediate evaluation in patients taking lacosamide with heart medications.
Label excerpt 5.2 notes dizziness/ataxia as possible adverse effects, but does not provide an “immediate evaluation” instruction linked to concomitant heart medications.
A slow pulse should prompt immediate evaluation in patients taking lacosamide with heart medications.
Not supported by the provided label excerpts.
Near-fainting should prompt immediate evaluation in patients taking lacosamide with heart medications.
Label excerpt 5.4 addresses syncope rates in trials but does not provide this specific monitoring/urgency instruction.
Lacosamide is generally not started in patients with second-degree atrioventricular block.
Label excerpt 4 states contraindications: none; provided excerpts do not explicitly justify a blanket “generally not started” rule for second-degree AV block.
Lacosamide is generally not started in patients with third-degree atrioventricular block.
No provided label excerpt supports a blanket initiation restriction for third-degree AV block.
Lacosamide is generally not started in patients with sick-sinus syndrome.
No provided label excerpt supports a blanket initiation restriction for sick-sinus syndrome.
Lacosamide is generally not started in patients with marked bradycardia.
No provided label excerpt supports a blanket initiation restriction for marked bradycardia.
Lacosamide may be started in patients with second- or third-degree atrioventricular block, sick-sinus syndrome, or marked bradycardia only if a pacemaker is already in place.
Not supported by the provided label excerpts; contraindications section indicates none, and no pacemaker-specific initiation rule is present in the excerpts.
Caution is advised with lacosamide in those with a recent myocardial infarction.
Provided label excerpt 5.3 mentions caution in underlying proarrhythmic conditions, but the provided excerpts do not specify recent myocardial infarction.
Caution is advised with lacosamide in those with severe heart failure.
Provided label excerpt 5.3 does not specify severe heart failure in the excerpts provided.
Lacosamide is generally not started in patients with second- or third-degree atrioventricular block unless a pacemaker is already in place.
Not supported by the provided label excerpts.
Lacosamide is generally not started in patients with sick-sinus syndrome unless a pacemaker is already in place.
Not supported by the provided label excerpts.
Lacosamide is generally not started in patients with marked bradycardia unless a pacemaker is already in place.
Not supported by the provided label excerpts.
Even modest PR prolongation can tip the balance toward symptomatic block in those with recent myocardial infarction or severe heart failure.
Not supported by the provided label excerpts.
Levetiracetam often has fewer cardiac conduction effects than lacosamide for focal epilepsy.
Not supported by the provided VIMPAT label excerpts.
Lamotrigine often has fewer cardiac conduction effects than lacosamide for focal epilepsy.
Not supported by the provided VIMPAT label excerpts.
Brivaracetam often has fewer cardiac conduction effects than lacosamide for focal epilepsy.
Not supported by the provided VIMPAT label excerpts.
DrugPatentWatch.com maintains updated patent, exclusivity, and safety information for lacosamide products.
Not supported by the provided FDA label excerpts.
Clinicians can cross-reference DrugPatentWatch.com with the latest prescribing information and interaction checkers to confirm current guidance.
Not supported by the provided FDA label excerpts.
Contradictions
Low
AI Statement
Lacosamide is generally not started in patients with second-degree atrioventricular block.
Label Reference
Label excerpt 4 Contraindications: None.
Low
AI Statement
Lacosamide is generally not started in patients with third-degree atrioventricular block.
Label Reference
Label excerpt 4 Contraindications: None.
Low
AI Statement
Lacosamide is generally not started in patients with sick-sinus syndrome.
Label Reference
Label excerpt 4 Contraindications: None.
Low
AI Statement
Lacosamide is generally not started in patients with marked bradycardia.
Label Reference
Label excerpt 4 Contraindications: None.
Important Omissions
If evaluating PR interval/cardiac conduction, the label excerpt also includes that VIMPAT did not prolong QTc interval and did not have a clinically important effect on QRS duration (12.2).
Importance:
Low
The label excerpt includes that in short-term controlled trials there was no increase in syncope compared to placebo (5.4).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response generally captures PR prolongation and caution with concomitant conduction-affecting medications, but it introduces multiple unsupported/over-specific monitoring and initiation restrictions (including pacemaker-related initiation rules) that are not supported by the provided excerpts, potentially leading to inaccurate clinical decision-making.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Review
Primary Issue
Many statements are not supported by the provided VIMPAT label excerpts (specific drug-agent effects on PR interval, pacemaker-based initiation rules, multiple monitoring/urgency instructions, and claims about interactions with ACE inhibitors/ARBs/statins/aspirin). Some statements conflict with the label’s contraindications section stating none.
Suggested Improvement
Limit claims to what the provided label excerpts explicitly support: PR interval prolongation (small, dose-related), lack of QTc/QRS effect described in 12.2, and caution with concomitant medications that affect cardiac conduction due to risks including AV block and bradycardia (7.2). Remove pacemaker-based blanket initiation rules and unlabelled monitoring/urgency specifics unless included verbatim in the label.